Nitric oxide (NO) is present in the breath exhaled from healthy humans. The location and subtype of the NOsynthase responsible for the expired NOare unknown. As dexamethasone inhibits the induction of NOsynthase, we evaluated the effect of administering dexamethasone (4 mg/day for 2 days) on the amount of NOexhaled by eight healthy men. The amount of NO showed a significant linear correlation with the duration of exhalation, allowing the rate of NOrelease to be calculated. The rate of NOrelease was 0.047±0.023 nmol/s before drug administration. There was no significant change in the release rate at the end of the 2-day administration of drug or at 5 days after cessation. Serumconcentrations of interferon-y and interleukin-ip were unaffected by the administration of dexamethasone. These results suggest that the NOreleased from the human airway under normal conditions is not generated by the action of inducible NOsynthase.
Introduction
Nitric oxide synthase (NOS)catalyzes the conversion of Larginine to nitric oxide (NO). Three isoforms ofNOShave been isolated, cloned, and sequenced. These isoenzymes can be divided into two subtypes based on activity (1) . Constitutive NOS(CNOS) is expressed by endothelial and neural cells and is stimulated as a result of cell receptor activation. Inducible NOS(iNOS) is induced in macrophages and other cells in vivo or in vitro by cytokines or lipopolysaccharides. Glucocorticoids inhibit the induction of iNOSvia a receptor-mediated event that involves the inhibition of the synthesis of mRNA for de novo synthesis of iNOS (1, 2) . Endogenous NO, generated by the action of NOS (3, 4) , is present in the breath of normal humans at~10 parts per billion (ppb) (3, 5, 6) , and at even higher levels in asthmatic patients (4, 7) . Immunohistochemical studies have demonstrated the presence of NOSin the lung, specifically in the pulmonary vascular endothelial cells (8, 9) , nerves (9, 10) , alveolar macrophages (9, 1 1) and airway epithelial cells (9, 12) . Nevertheless, the regulation of NOmetabolism in the lung and airways is not well understood.
Sometypes of cells in the respiratory system can demonstrate iNOSactivity. While there is no conclusive proof that NO is formed from L-arginine in human macrophages ( 1 3) , there is indirect evidence of NOformation in alveolar macrophages (ll, 14) . Alveolar macrophages from normal subjects also contain mRNAsfor cytokines, specifically IL-1J3 (15) . Human macrophagesthat have matured in vitro release substantial amounts ofnitrite, the metabolite of NO,even in the absence of overt stimulation (16) . The epithelium mediates the interaction between the lung and inhaled oxidants. Oxidative stress induces iNOS in human epithelial cells via the induction of the transcription factor ( 1 7). The combination of IL-1 (3, IFN-y, and TNF-oc induces iNOS in murine lung epithelial cells (1 8) and in rat type II pneumocytes (19). In the latter instance, the production of NOis increased after the inhalation of a pulmonary irritant. Marked iNOS immunoreactivity has been detected in the epithelium of histologically normal humanairways and occasionally, in the alveolar macrophages and endothelium (9) . Hamid et al detected iNOSimmunoreactivity in the epithelium and in some inflammatory cells in the lungs of individuals with asthma. They also observed immunoreactivity , although less frequently , in the nonasthmatic controls (12) . Alving et al suggest that NO in exhaled air originates mainly in the nasopharyngeal airways (7). This hypothesis has been supported by Gerlach et al, who suggest that bacteria or bacterial toxins maystimulate the nasal mucosa to synthesize NO(20). It is not knownwhich NOSsubtype is responsible for the major portion of NOexhaled by healthy humans, but the above observations suggest that iNOS maybe active in normal human alveolar macrophages , lung epithelium, or nasal airways under basal conditions. Under conditions in which iNOSis expressed, most of the NO produced is due to iNOS activity (1, 2) . Levels of NOin exhaled air vary more than 10 fold among normal individuals without respiratory symptoms (unpublished observations). This wide variation indicates that iNOSmay contribute to the production of NOin the exhaled air of apparently healthy people. In the present study, dexamethasone was administered to healthy subjects to block the induction of iNOS (21). The effect of such dexamethasone administration on the amount of exhaled NOwas measured.
Materials and Methods

Subjects
Eight Japanese male volunteers aged 33+8 years were enrolled in the study. They had no symptoms of respiratory disease and none was receiving medication. Subjects who smoked (n=4) were asked to refrain from smoking for at least 1 hour before the initiation of the study. The study was approved by the institutional committee on humanresearch. Informed consent for participation was obtained from each subject.
Proto col
Each subject was allowed to sit and breathe normally for 10 minutes, after which the blood pressure was measured with a sphygmomanometer. Samples of venous blood and exhaled air were collected as described below. Dexamethasone (Corson; Takeda Yakuhin, Osaka) was administered at a dose of 1 mg every 6 hours for 2 days. Within 4 hours after, and again at 5 days after the last dose of dexamethasone, blood pressure was re-measured and specimens of venous blood and exhaled air were collected.
Collection of exhaled air samples Roomtemperature was maintained at -25°C and the relative humidity at <60%. After inspiration through the mouth, air was exhaled through the mouth. Noseclips were not used to allow air in the nasopharyngeal space to easily diffuse into the atmosphere during the exhalation. Under specific instructions, the subject exhaled through a mouthpiece connected to a 6 liter bag made of polyvinylfluoride film (Tedlar bag; Iuchi, Tokyo). A Teflon column (15 x 50 mm) packed with 6.7 g ofanhydrous silica gel (particle size, 1.7 to 4.0 mm; Kanto Chemical, Tokyo) was inserted between the mouthpiece and the Tedlar bag. The silica gel dried the exhaled air sufficiently to prevent the condensation of vapor on the walls of the Tedlar bag, even after the exhalation of 1 0 deep breaths. Nitric oxide was not adsorbed by the silica gel and was stable in the Tedlar bag for several hours if the sample remained dry and Tedlar bags containing samples were protected from light until analysis. In four calibration trials, air containing NOat 10 ppb was passed through the silica gel column. The concentrations measured after 0, 2, 4, and 6 hours in the bag were 9.9±0.1, 9.9±0.1, 9.8+0.2, and 9.5+0.3 ppb, respectively. When humid air was exhaled directly into the bag, the concentration of NO decreased by -20% within 30 minutes (from 1 1.2±3.4 to 8.8±5.2 ppb, n=4). The study was performed only when the concentration of NOin room air was <3ppb.
NOgas analysis and rate of NOrelease In airway Nitric oxide concentration was measured with a chemiluminescence analyzer (Model GLN-32; Denki-Kagaku-Keiki, Tokyo), that detects photons generated by the oxidation of NO by ozone. The photomultiplier signal was amplified and recorded with a recorder (Model 056; Hitachi, Tokyo). The flow rate for sampling was 800 ml/min, and the recorded curve for the applied sample reached steady state in 3 minutes. The minimumlimit and the resolution for the detection of NOwas 0.2 ppb. The coefficient of variation was 2%at 20 ppb NO. Before use, the instrument was calibrated by NOat 100 ppb in nitrogen (Sumitomoseika, Chiba) before use. Each gas analysis was performed within 1 hour after collection.
The relationship between the amount of NOin the exhaled air and the duration of exhalation was analyzed. Subjects were instructed to exhale air, after a full inspiratory effort, at six different speeds of exhalation that were determined arbitrarily by each subject from very fast to very slow. The volume of air was recorded in each instance and corresponded to the vital capacity. Subjects practiced the procedure several times. The order of the speed of exhalation was randomized. The six samples were collected in separate bags. More than 2 minutes elapsed between each sampling. The time from the start to the end of each sampling was measured with a stopwatch and ranged from 1 1.7 to 70.0 seconds, depending on the ability of the subject. The protocol was repeated 10 times within 3 weeks in one volunteer who had no symptomsof respiratory disease during the weeks. The amount of NO(nmol) in the exhaled air sample was calculated from b x V x 24.5"1; where b (ppb) is the NOconcentration of the exhaled air sample, V (liter) is the sample volume, 24.5 (liter) corresponds to the volume of 1 mol of ideal gas at 25°C at 760 mmHg.Because the amount of exhaled NOexhibited a positive correlation with the duration of exhalation, a simple linear regression model based on the leastsquares methodwas applied. The slope was regarded as the rate of NOrelease from the airway.
Measurement of cytokines and cortisol
The serum concentration of IFN-y was determined by a radioimmunoassay, as described previously (22 value was significant, Scheffe's test was applied. Ap value of <0.05 was considered statistically significant.
Results
The serum cortisol concentration was 1 2.4+3.6 mg/dl before the administration of dexamethasone, below the detection limit ( 1.0 mg/dl) at the end of the 2-day administration, and 1 1.3±2.2 mg/dl on the 5th day after administration. The individual blood pressure, pulse rate, and serum concentrations of sodium, potassium and chloride were all within the normal range, and did not vary significantly among the three points of measurement of the protocol. The concentration of NOin room air averaged 0.8+0.6 ppb (0-2.5 ppb) immediately before initiation of the protocol. On rainy days, the concentration of NOin room air often exceeded 3 ppb. The protocol was not performed until the NOconcentration in the room dropped to less than 3
ppb. The NOconcentration of the air samples exhaled fastest all exceeded the NOconcentration in room air.
There was a significant positive correlation between the duration of exhalation and the amount of exhaled NO (Fig. 1) .
The slope (nmol/s) of the linear regression relation between the amount of NOexhaled and the duration of exhalation was taken as the rate of NOrelease in the airway. This rate was not significantly affected by the administration of dexamethasone for 2 days (0.047±0.023 nmol/s before administration, 0.045±0.017 nmol/s at the end of administration, and 0.043±0.015 nmol/s 5 days afterwards) (Fig. 2) . There was no significant difference in the rate of NOrelease between the smokers and nonsmokers. The rate of NOrelease was constant (0.035+0.004 nmol/s) in the one subject who repeated the protocol 10 times over a 3-week period.
The administration of dexamethasone did not affect the serum concentration ofIFN-y (0.9+0.2 U/ml before administration, 0.8±0.2 U/ml at the end of administration, and 0.9±0.2 U/ ml 5 days after the cessation of administration). There was no correlation between the serum concentration of IFN-y and the rate of NO release (p=0.69, 0.31, and 0.29, respectively).
The serum concentration of IL-l p was below the limit of detection in our analysis (10 pg/ml) at all time points.
Discussion
In healthy humans, a two-day regimen of oral dexamethasone did not affect NO release by the respiratory system.
Massaro et al (23) reported that parenteral administration of glucocorticoid ( 1 80-240 mg methylprednisolone over 4-24 hours, or a single 40 mgdose ofprednisolone) in patients with acute asthma causes a reduction in expired NO. This decrease was evident as early as 48 hours after the initiation of therapy (180-240 mg of methylprednisolone over 4-24 hours). The antiinflammatory potency of dexamethasone is 5-fold higher than that of methylprednisolone and 6.25-fold higher than that ofprednisolone (24). The biological half-life of dexamethasone (36 to 72 hours) is larger than that of methylprednisolone or prednisolone (12 to 36 hours) (24). Although the dose of dexamethasone administration in the present study had no more than half the antiinflammatory potency of the steroid treatments reported by Massaro et al, the extended period of administration and the prolonged biological half-life of dexamethasone should have compensated for the reduced dosage with respect to the inhibition of iNOSactivity. Cytokines increase the expression ofiNOSmRNA in a doseand time-related manner. This effect is mediated by transcriptional activation and is followed by the de novo appearance of iNOS protein (25). The half-life ofiNOS mRNAis~6 hours in cultured cells (26). Studies in vivo have shown that the induction of iNOS causes mRNA levels to peak at~6 hours and elevated levels of mRNApersist for 24 hours in the rat mesentery (27) or 18 hours in the ratmyocardium (28). Ithas also been shown that, after iNOS has been induced, the release of NOmay continue for several days (2, 21, 29) . In the present study, the rate of NOrelease in the one volunteer tested periodically remained constant over a period of weeks. These observations support the hypothesis that iNOS activity is relatively constant under basal conditions as a result of a balance between degradation and cytokine-induced synthesis. Dexamethasone treatment over a period of2 days would be expected to reduce iNOS activity and, consequently, reduce NO production in the total respiratory system, only if iNOS activity made a significant contribution to the expired NO. The site of origin of NOin the respiratory system remains controversial. Persson et al have suggested an airway origin, specifically the terminal and respiratory bronchioles, based on their observations ofa NOpeak in single exhalations (6, 30) . It has also been suggested that NO in exhaled air originates mainly in the nasal airways (7, 20) . However, if NOwas diffusing from the nasopharynx, the concentration of NOwould be highest in the dead space. It has been shown that measurement of NOand carbon dioxide exhibit the same delay before increasing after the beginning ofa single oral exhalation (6) . Air is prevented from leaking from the nasopharynx into the oral cavity by the soft palate. The soft palate rises, and moves backward against the pharynx, to thus close off access to the nasal space above (31). It is reasonable to assume that pulmonary exhaled gas was relatively uncontaminated by nasopharyngeal gas.
The fact that the administration of dexamethasone did not affect NOrelease from the respiratory airways indicates that the NOexhaled in normal subjects is unlikely to be generated as a result of the activity ofiNOSlocalized in the airway. This result supports the observation of Kharitonov et al (4) that in asthmatic patients, inhaled steroids can reduce the amount of NOto values seen in normal individuals (but not to lower values). There appears to be a basal level of exhaled NOwhich is not influenced by the administration of steroids. It is of interest to note that the subject with the highest NOvalues before administration of dexamethasone (no. 5 in Fig. 1 ) had a significant (-40%) drop in exhaled NOafter treatment. This profile suggests that the synthesis ofiNOS had been induced in this patient and was inhibited by dexamethasone. A simple model yielding the concentration (C, mol/liter) of _4-°l No Duration of exhalation (s) Duration of exhalation (s) Figure 1 . The relation between the amounts of NOexhaled and the duration of exhalation in each subject before ( O ), at the end of ( å¡ ), and 5 days after ( A ) administration of8 mg of dexamethasone over 2 days. Single regression analysis with the least-squares method revealed a significant correlation between variables (p<0.013 for all subjects at all points).
gas in the sampling container after time (t, sec) was derived as follows: C=P x t x 1/V, where P (mol/sec) was the average NO release over time and V (liter) was the air volume collected. Whenthe equation was converted to C x V=Px t, where C x V corresponds to the amount of NO(mol) in the exhaled air sample and P corresponds to the slope versus time, the rate of NOrelease (P) was found to be constant because the amount of NOin the sample (C x V) showed a linear relation to the duration of exhalation (Fig. 1) . Therate of NOrelease refers to the rate of elimination or expiration, but not the rate of NOproduction, in the airway. The NOrelease rate and NOproduction rate would be equal only if it were known that no NOwas scavenged by the lung tissue or by capillary red blood cells. Uptake of exogenous NOfrom alveolar air, probably by capillary red blood cells, has been demonstrated (32). Breath-holding causes an elevation of NO NOis stable in dry air when it is protected against ultraviolet light. Adsorption of NOby the silica gel column and the Tedlar bag was negligible, thus allowing the calculation of the rate of NOrelease. The value of the intercept in the relationship between NOconcentration and duration of exhalation may have represented the initial concentration in the respiratory system just prior to exhalation, a combination of atmospheric NOand the NOpre-existing in the airway. The level of atmospheric NO did not fluctuate significantly in the time necessary to complete the protocol with any given subject. The slope did not vary with the level of atmospheric NOover several samplings. Thus, NO release in the airway could be estimated. Thevascular endotheliumalso expresses iNOSin response to exposure to cytokines such as IFN-y (33). The iNOS activity of vessels may thus be associated with circulating concentrations ofcytokines. Borland et al have suggested that pulmonary endothelium-derived NOmay enter the airspace in sufficient amounts to allow its measurement in exhaled air (34). The lack of correlation between the serum concentration of IFN-y and the NOrelease rate in the present study suggests that pulmonary endothelium-derived NOgenerated by the action of IFN-y does not contribute significantly to released NO. The results of this study suggest that, in healthy individuals, NOgenerated by iNOS makes a negligible contribution to the total exhaled NO. The NOpresent in expired air is probably generated by CNOSin non-alveolar regions of the respiratory system.
